FDA Approves New Combination Treatment for High-Risk Bladder Cancer

The U.S. Food and Drug Administration has approved durvalumab in conjunction with Bacillus Calmette-Guerin for adult patients diagnosed with high-risk non-muscle invasive bladder cancer. This regulatory decision was based on clinical data demonstrating a statistically significant improvement in disease-free survival for individuals receiving the combined therapy. The approval offers a new treatment option for this specific patient population.